Back to search
FDAFDA · Food and drugs·Recall number D-0747-2022

NETSPOT (kit for the preparation of Ga 68 dotatate injection) 40 mcg dotatate, kit contains Vial 1 (Reaction vial with lyophilized powder), 1 Single dose vial, consisting of 40 mcg of dotate, 5 mcg of 1,10-phenanthroline, 6 mcg of Gentisic acid, 20 mg of D-Mannitol, and Nitrogen; and Vial 2, 1 Single dose vial of reaction buffer, Rx Only, Manufactured for: Advanced Accelerator Applications USA, Inc., by: Gipharma S.r.l., Strada Crescentino snc, 13040 Saluggia (Vc), Italy, NDC 69488-001-40

Published April 13, 2022 · Recall initiated: March 18, 2022

Summary

FDA records drug Class III recall D-0747-2022, published April 13, 2022 and initiated March 18, 2022. Recalling firm: Advanced Accelerator Applications USA, Inc.; Status: Terminated; Reported quantity: 14,089 kits; Lot: Lot # (Vial 1)/kit: (F03221004 vial) in kit PG1921014, PG1921015, Exp 16-Mar-2022; (F03221005 vial) in kit PG1921016, PG1921017, Exp 18-Mar-2022; (F03221006 vial) in kit PG1921018, PG1921019, Exp 11-May-2022; (F03221007 vial) in kit PG1921020, PG1921021, Exp 04-Aug-2022. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Subpotent Drug: low out-of-specification results for Vial 1 assay obtained during stability studies.

What to do

Voluntary: Firm initiated · Letter

Get an email if NETSPOT has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
NETSPOT
Manufacturer
Advanced Accelerator Applications USA, Inc.
Distributor
Nationwide in the USA and Puerto Rico
Lot
Lot # (Vial 1)/kit: (F03221004 vial) in kit PG1921014, PG1921015, Exp 16-Mar-2022; (F03221005 vial) in kit PG1921016, PG1921017, Exp 18-Mar-2022; (F03221006 vial) in kit PG1921018, PG1921019, Exp 11-May-2022; (F03221007 vial) in kit PG1921020, PG1921021, Exp 04-Aug-2022
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was NETSPOT (kit for the preparation of Ga 68 dotatate injection) 40 mcg dotatate, kit contains Vial 1 (Reaction vial with lyophilized powder), 1 Single dose vial, consisting of 40 mcg of dotate, 5 mcg of 1,10-phenanthroline, 6 mcg of Gentisic acid, 20 mg of D-Mannitol, and Nitrogen; and Vial 2, 1 Single dose vial of reaction buffer, Rx Only, Manufactured for: Advanced Accelerator Applications USA, Inc., by: Gipharma S.r.l., Strada Crescentino snc, 13040 Saluggia (Vc), Italy, NDC 69488-001-40 recalled?

Yes. FDA published recall D-0747-2022 on April 13, 2022. Reported hazard: Subpotent Drug: low out-of-specification results for Vial 1 assay obtained during stability studies.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: NETSPOT.